15 02 Metastasis Base Architecture HG Prostatic Adenocarcinoma

Metastatic prostatic adenocarcinoma exhibits profound site-specific heterogeneity, with distinctprogression patterns across bone (dominant site, 70-85% incidence), lymph nodes (20-30%),liver (10-15%), and lung (8-12%) [1,2]. Traditional clinical paradigms treat metastases as homogeneous entities responding uniformly to androgen deprivation therapy (ADT). However,emerging evidence demonstrates that each metastatic site constitutes a distinct **ecosystem** with unique biochemical constraints, adaptive strategies, and therapeutic vulnerabilities